PDCD1 and neoplasm: These pharmacologic agents operate by attenuating the interactions between PD-1 and PD-L1, thereby ameliorating immune suppression and potentiation of anti-tumor immune responses, consequently impairing the neoplastic cells' ability to elude immunological surveillance [27, 28].